Zachariah Jonasson, Ph.D., serves as the Chief Financial Officer (CFO) and Chief Business Officer at Absci Corp, a pioneering company in the field of synthetic biology and AI-driven drug discovery. Dr. Jonasson's role at Absci involves overseeing the company's financial strategy and business development initiatives, ensuring that the company's innovative approach to drug discovery translates into sustainable growth and value creation. His dual role as CFO and CBO positions him uniquely to bridge the gap between the company's scientific endeavors and its commercial objectives, driving Absci's mission to revolutionize the biopharmaceutical industry. Prior to joining Absci, Dr. Jonasson held several senior leadership positions that honed his expertise in finance and business strategy within the life sciences sector. He has a robust background in investment banking, having worked at firms such as Morgan Stanley and Goldman Sachs, where he specialized in healthcare and biotechnology. His experience in these roles equipped him with a deep understanding of capital markets and corporate finance, which he leverages effectively at Absci. Additionally, Dr. Jonasson's academic credentials are equally impressive; he holds a Ph.D. in Biochemistry from Stanford University, which provides him with a solid foundation in the scientific principles underpinning Absci's technology. Dr. Jonasson's achievements in his career are numerous and impactful. At Absci, he has been instrumental in securing significant funding rounds that have propelled the company's growth and expanded its research capabilities. His strategic foresight and ability to forge key partnerships have been critical in positioning Absci at the forefront of the AI-driven drug discovery landscape. Under his leadership, Absci has successfully navigated the complex interplay between cutting-edge science and the financial imperatives of a burgeoning biotech firm, cementing its reputation as a leader in the industry.